Skip to main content

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

Volume 10, Number 2, March 2010

Articles

ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
pp. 127-134(8)
Authors: Micuda, S.; Rosel, D.; Ryska, A.; Brabek, J.

Favourites:
ADD

Understanding FOXO, New Views on Old Transcription Factors
pp. 135-146(12)
Authors: Zanella, F.; Link, W.; Carnero, A.

Favourites:
ADD

Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
pp. 147-154(8)
Authors: Izzotti, A.; Longobardi, M.; Cartiglia, C.; D'Agostini, F.; Kanitz, S.; De Flora, S.

Favourites:
ADD

Free Content Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
pp. 155-167(13)
Authors: K. Gandhi, A.; Kang, J.; Capone, L.; Parton, A.; Wu, L.; H. Zhang, L.; Mendy, D.; Lopez-Girona, A.; Tran, T.; Sapinoso, L.; Fang, W.; Xu, S.; Hampton, G.; B. Bartlett, J.; Schafer, P.

Favourites:
ADD

Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
pp. 168-175(8)
Authors: Zoppoli, G.; Moran, E.; Soncini, D.; Cea, M.; Garuti, A.; Rocco, I.; Cirmena, G.; Grillo, V.; Bagnasco, L.; Icardi, G.; Ansaldi, F.; Parodi, S.; Patrone, F.; Ballestrero, A.; Nencioni, A.

Favourites:
ADD

Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
pp. 176-191(16)
Authors: E. Favoni, R.; Pattarozzi, A.; Casto, M.; Barbieri, F.; Gatti, M.; Paleari, L.; Bajetto, A.; Porcile, C.; Gaudino, G.; Mutti, L.; Corte, G.; Florio, T.

Favourites:
ADD

Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors
pp. 192-199(8)
Authors: Colombo, S.; Palmioli, A.; Airoldi, C.; Tisi, R.; Fantinato, S.; Olivieri, S.; De Gioia, L.; Martegani, E.; Peri, F.

Favourites:
ADD

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
pp. 200-209(10)
Authors: Navid, F.; M. Santana, V.; C. Barfield, R.

Favourites:
ADD

Inhibitors of HDACs - Effective Drugs Against Cancer?
pp. 210-228(19)
Authors: Muller, S.; H. Kramer, O.

Favourites:
ADD

Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
pp. 229-241(13)
Authors: Yu, Lunyin; G. Garg, Hari; Li, Boyangzi; J. Linhardt, Robert; A. Hales, Charles

Favourites:
ADD

The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
pp. 242-267(26)
Authors: Hingorani, M.; Spitzweg, C.; Vassaux, G.; Newbold, K.; Melcher, A.; Pandha, H.; Vile, R.; Harrington, K.

Favourites:
ADD

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more